Answer
Yes, Soliris (eculizumab) can cause infusion reactions or immunogenicity leading to allergic or hypersensitivity reactions, including anaphylaxis; severe infusion reactions require interruption of administration and appropriate medical therapy.
Sources for this answer
- Soliris 300 mg concentrate for solution for infusionAlexion Pharma UK Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 29Document updated
Sources checked